

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

PROCESSED BY
JAN 23 1998
FII

In re Application of

Boyle et al.

Application Number

026,957

Filed

3-5-93

Group Art Unit

Examiner

Robert D. Budens

Paper No. #19

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- ___ (A) referred to in United States Patent Number 5654407, column _____
- ___ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____
- ___ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- ___ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Denise English

Signature

Denise English

Typed or printed name

1-23-98

Date

FOR PTO USE ONLY

Approved by: SA
(Initials)

Unit: _____

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



US005654407A

United States Patent [19]

Boyle et al.

[11] Patent Number: 5,654,407

[45] Date of Patent: Aug. 5, 1997

[54] HUMAN ANTI-TNF ANTIBODIES

[75] Inventors: Petra Boyle, Pinole; Gayle D. Wetzel, Martinez; Kenneth J. Lembach, Danville, all of Calif.

[73] Assignee: Bayer Corporation, Berkeley, Calif.

[21] Appl. No.: 435,246

[22] Filed: May 5, 1995

Related U.S. Application Data

[63] Continuation of Ser. No. 145,060, Oct. 29, 1993, abandoned, which is a continuation-in-part of Ser. No. 26,957, Mar. 5, 1993.

[51] Int. Cl.⁶ C07K 16/24

[52] U.S. Cl. 530/388.15; 424/142.1; 424/145.1; 424/158.1; 435/335; 530/388.23; 530/388.24

[58] Field of Search 424/142.1, 145.1, 424/158.1; 435/70.21, 172.2, 335; 530/388.15, 388.23, 388.24, 389.2

[56]

References Cited**PUBLICATIONS**Rhein, R., "Another Sepsis Drug Down—Immunex' TNF Receptor," *Biotechnology Newswatch* Oct. 4, 1993, McGraw Hill, Publishers., pp. 2-3.Boyle et al., "A Novel Monoclonal Human IgM Autoantibody Which Binds Recombinant Human and Mouse Tumor Necrosis Factor- α ," *Cell. Immunol.* 152:556-568, 1993.Boyle et al., "The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF α on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope," *Cell. Immunol.* 152:569-581, 1993.

Primary Examiner—Robert D. Budens

Attorney, Agent, or Firm—James A. Giblin

[57]

ABSTRACT

Human monoclonal antibodies (mAbs) which bind to human TNF α are disclosed. Autoantibodies of both the IgM and IgG isotypes are disclosed. A preferred human monoclonal antibody is known as B5 (F78-1A10-B5 mAb) and it binds to recombinant human TNF α (rhTNF α) in ELISA format with a titer comparable to three high affinity neutralizing mouse mAbs. It also binds to cell surface TNF α and prevents TNF α secretion by human monocyte cell lines.

12 Claims, 11 Drawing Sheets